Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05848856

The RISC Registry--Risk Informed Screening Registry

Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Six in ten adults have one chronic disease; 4 in 10 have two or more. These are also leading drivers of the nation's $4.1 trillion in annual health care costs.

Cardiovascular disease is the number one cause of death for men and women, cancer is the second largest, with breast cancer being the second largest cause of death in women. Diabetes is the 8th highest cause of death for both men and women.

Routine screening, a focus on prevention, early detection, and patient engagement with proposed care plans, effective surveillance and follow up are some of the most effective ways to reduce the burden of chronic diseases across an individual's lifetime and at the population level.

Estimating dollar costs associated with non-compliance with screening and health management recommendations is complex and variable depending on the specific context, disease, and condition. But there is much evidence to indicate that a significant amount of these annual costs can be mitigated if compliance with health management recommendations increases, and health problems are prevented or detected early.

Access to screening and noncompliance with health management recommendations impact the entire population, but more disparities exist in racial and ethnic minorities and in the historically underserved for cancer, obesity, diabetes and cardiovascular disease.

The overall cost of these disparities in the U.S. has been estimated at around 1.24 trillion U.S. Dollars.

The RISC Registry seeks to pursue the intersection of breast cancer, metabolic, and cardiovascular risk in women and study the application of individualized multi-condition risk assessments, risk-informed or personalized screening, prevention and follow up care approaches in a broad cross section of patients. It pursues the hypothesis that these approaches accompanied by population appropriate methods of clinician and patient engagement may increase understanding and compliance with breast cancer, obesity, and metabolic/cardiovascular/cardiometabolic risk screening, surveillance and follow up recommendations by empowering women to make healthier choices.

In doing so, these methods may identify ways to address disparities in screening and patient care and ultimately promote early detection or even reversal of adverse health conditions, improve overall personal health, and reduce overall health care costs.

The primary focus is cancer, cardiovascular and metabolic health screening with a focus on utilization of Precision Screening. (Precision Screening attempts to separate those who will benefit from screening from those that may not, through use of information on disease risk.)

The study will start by focusing on women and risk for these diseases and health conditions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Risk Arterial Occlusive Diseases Arteriosclerosis Body Weight Breast Diseases Breast Neoplasms Cardiometabolic Risk Cardiovascular Disease Risk Cardiovascular Diseases Coronary Artery Disease Coronary Disease Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Heart Diseases Metabolic Diseases Myocardial Ischemia Neoplasms Neoplasms by Site Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases Vascular Diseases

Age range

18 year–100 year

Sex eligibility

Female

Study type

Observational

Primary location

About this study

The RISC Registry (the "Registry") is a longitudinal observational database designed to capture health information that inform individualized disease risk and care plans in varied and diverse patient populations and study how that information impacts physician recommendations and patient compliance.

The Registry was designed by a board of Scientific Advisors who are active users of risk assessment tools, and risk-informed screening protocols, including physicians, nurses, and patient advocates. Technology professionals and site administrators were also consulted regarding optimizing the process of data collection and dissemination. The Registry uses widely accepted standards for risk and disease classifications, results, management, and validated quality-of-life measures.

The Registry is vendor-agnostic and product-agnostic. This study will make a special effort to reach women who have historically been underserved by recruiting patients broadly distributed across different socioeconomic groups, ethnicities and diverse geographic areas.

The RISC Registry will help determine the ongoing value of Precision Screening in different clinical patient populations, shape guidelines for screening and optimal patient management, and support improvements in Precision Health and Precision Medicine support technology.

Eligible subjects will be offered multi-disease personalized risk assessments and care plans at no charge to reduce cost as a barrier to screening.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female (Gender assigned at birth)
  • Unaffected women (by breast cancer, diabetes or cardiovascular disease)
  • Females who have been diagnosed with breast cancer, diabetes or cardiovascular disease
  • Females who are presenting for cancer, metabolic health or cardiovascular screening
  • Females presenting for mammography or other breast cancer screening procedures
  • Females presenting for cholesterol, other blood tests aimed at metabolic and cardiovascular health screening, ECG's, EKG's or other noninvasive scans for the presence of or risk of heart disease
  • Ages 18+
  • Willing to sign a study consent form
  • Willing to participate in PRO surveys
  • Willing to use technology to participate in the study procedures, if and as needed
  • Pregnant women may be included

Treatment and study plan

Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up

Behavioral

Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement

Primary outcomes

  1. Disease risks and issues identified during multi-condition risk assessment

    Time frame: Within 3 months

    Types of disease risks or issues identified by implementing a multi-condition risk assessment in a single patient.

  2. Objective health measures within different population subgroups--blood pressure

    Time frame: Within 6 months

    Changes in an individual's blood pressure (both systolic and diastolic) tracked over time associated with different risk assessments, recommended care plans and patient engagement techniques, by different population subgroups. Could include data gathered from connected health devices used as part of the care plan and follow up.

  3. Objective health measures within different population subgroups--BMI

    Time frame: Within 6 months

    Changes in an individual's BMI using combined height and weight measures, tracked over time, associated with different cardiovascular and breast cancer risk assessments, recommended care plans and patient engagement techniques, by different population subgroups.

  4. Objective health measures within different population subgroups--HDL levels

    Time frame: Within 6 months

    Changes (increase or decrease) in an individual's HDL tracked over time associated with different risk assessments, recommended care plans and patient engagement techniques, by different population subgroups.

  5. Objective health measures within different population subgroups-- abnormal germline genetic test results

    Time frame: Within 6 months

    Prevalence of abnormal germline genetic test results for cardiovascular and breast cancer disease risk, by different population sub groups

  6. Number of subjects with newly diagnosed early stage cardiometabolic conditions and breast cancer

    Time frame: Within 6 months

    Early detection as measured by stage/extent of disease, linked to different risk assessments, care plans and patient engagement techniques, within different population subgroups.

  7. Cancer health outcomes--imaging follow up

    Time frame: Within 1 year

    Short term cancer health outcomes using RECIST (Response Evaluation Criteria in Solid Tumors) to analyse how well treatment has worked as measured or detected by imaging results

  8. Short and Long term cancer health outcomes--biospecimen tests

    Time frame: Within 1 year

    Short--within one year and longer term --within 5 years--cancer health outcomes using survival measure scales including Progression Free Survival (PFS) correlated with biospecimen tests that detect presence of disease.

  9. Short and Long term cancer health outcomes--biospecimen tests

    Time frame: Within 1 year

    Short--within one year and longer term --within 5 years--cancer health outcomes using survival measure scales including Event Free Survival (EFS--complications and events the treatment was supposed to prevent) correlated with biospecimen tests that detect presence of disease.

  10. PRO--Patient Reported Outcomes: Percent of time patient screening behaviors changed based on recommendations made by shared decision making with the clinician

    Time frame: Within 3 months

    Patient behavior correlated with recommendations evaluated by type of method of engagement and various social drivers of health (SDOH) using the PRAPARE survey (https://prapare.org/the-prapare-screening-tool/)

  11. PRO--Patient Reported Outcomes: compliance with post screening recommendations

    Time frame: Within 3 months

    Patient compliance with recommendations evaluated by type of method of engagement and various social drivers of health (SDOH) as measured by using the PRAPARE survey (https://prapare.org/the-prapare-screening-tool/)

  12. Clinician--Recommendations based on multi-condition risk assessments

    Time frame: Within 1 month

    Types of recommendations and percent (%) of time they change based on precision risk assessments

Study contacts

Contact information is provided by the study sponsor or research team.

Greg Wolff

CONTACT

[email protected]

Mary Kay Hardwick, MBA

CONTACT

[email protected]

5106826256

Sponsors and collaborators

Lead sponsor

Precision Health Equity Initiative

Other

Registry information

Official study title

The Risk Informed Screening Registry (The RISC Registry)

Acronym: RISC

Important dates

Study start
2024
Primary completion
2034
Study completion
2035
First posted
May 8, 2023
Registry last updated
Jul 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.